ADMA Biologics (ADMA) Fundamental Analysis: Revenue, Earnings & Valuation

1.05 / 10

Underperform

Fundamentals are underperforming, scoring 1.1/10. Inventory and receivables turnover show modest efficiency, but PB‑ROE, Asset‑MV and revenue‑MV are negative, indicating poor quality and constrained upside.

Analysis Checks(7/10)

Revenue-MV

Value-1.27

Score1/3

Weight31.41%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value19.63

Score2/3

Weight3.15%

1M Return0.58%

Inventory turnover ratio

Value1.15

Score2/3

Weight-3.73%

1M Return-0.66%

Accounts receivable turnover ratio

Value4.90

Score2/3

Weight-3.33%

1M Return-0.65%

PB-ROE

Value5.88

Score0/3

Weight24.36%

1M Return3.80%

Income tax / Total profit (%)

Value19.56

Score2/3

Weight20.52%

1M Return3.20%

Fixed assets turnover ratio

Value7.56

Score3/3

Weight4.43%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.86

Score2/3

Weight-3.76%

1M Return-0.73%

Cost of sales ratio (%)

Value42.61

Score2/3

Weight-3.69%

1M Return-0.74%

Asset-MV

Value-0.55

Score0/3

Weight30.64%

1M Return4.88%

Is ADMA undervalued or overvalued?

ADMA scores 1.05/10 on fundamentals and holds a Premium valuation at present. Backed by its 35.56% ROE, 28.80% net margin, 15.61 P/E ratio, 4.80 P/B ratio, and -27.06% earnings growth, these metrics solidify its Underperform investment rating.